Top Tweets for #Checkmate274
๐ Updated data from #CheckMate274 at #ESMO2025 showed patients with advanced #UrothelalCancer continued to derive benefit from adjuvant #Opdivo @bmsnews after 5 years.
๐จ๏ฟฝ๏ฟฝ๏ฟฝ โThe benefit was rock stable,โ Dr. Matthew D. Galsky @TischCancer told Healio.
https://t.co/9sbdpBOZHQ
โ
#CheckMate274 helped lead to #FDA approval of adjuvant #nivoluamb for patients with advanced #UrothelalCancer.
๐ data from #ESMO2025 show patients with ctDNA-positive tests had โenrichedโ benefit, Dr. Matthew D. Galsky @TischCancer told @GoHealio.
https://t.co/9sbdpBOZHQ
Adjuvant nivolumab vs placebo for high-risk muscle invasive #UrothelialCarcinoma: 5-year efficacy and ctDNA results from #CheckMate274. Presentation by Matthew Galsky, MD @IcahnMountSinai. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/JTnVaLLVGA @myESMO
Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in @NatureMedicine @MattGalsky | 1. Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit 2. Composite model development is the key to select those pts with high risk features who benefit the most from adj Nivo @IBCG_BladderCA @urotoday @Medscape @SanRaffaeleMI @MyUniSR #Adjuvant #Bladdercancer #MedTwitter
https://t.co/xN9pMgAj8Q
#CheckMate274 analysis shows improved outcomes for #BladderCancer patients with adjuvant nivolumab. @MattGalsky @TischCancer sits down with @UroDocAsh @MDAndersonNews to discuss on UroToday.
๐น DFS benefit, esp. in PD-L1-high pts
๐น Neoadjuvant chemo? Nivo benefit remains
๐น #NIAGARA vs. risk-adapted IO timing debate
๐น #MODERN study: Can ctDNA guide treatment intensity?
#WatchNow > https://t.co/JlbPEP4rSZ
#CheckMate274 analysis shows improved outcomes for #BladderCancer patients with adjuvant nivolumab. @MattGalsky @TischCancer sits down with @UroDocAsh @MDAndersonNews to discuss on UroToday.
๐น DFS benefit, esp. in PD-L1-high pts
๐น Neoadjuvant chemo? Nivo benefit remains
๐น #NIAGARA vs. risk-adapted IO timing debate
๐น #MODERN study: Can ctDNA guide treatment intensity?
#WatchNow > https://t.co/JlbPEP4rSZ
#CheckMate274 analysis shows improved outcomes for #BladderCancer patients with adjuvant nivolumab. @MattGalsky @TischCancer sits down with @UroDocAsh @MDAndersonNews to discuss on UroToday.
๐น DFS benefit, esp. in PD-L1-high pts
๐น Neoadjuvant chemo? Nivo benefit remains
๐น #NIAGARA vs. risk-adapted IO timing debate
๐น #MODERN study: Can ctDNA guide treatment intensity?
#WatchNow > https://t.co/JlbPEP4rSZ
#CheckMate274 analysis shows improved outcomes for #BladderCancer patients with adjuvant nivolumab. @MattGalsky @TischCancer sits down with @UroDocAsh @MDAndersonNews to discuss on UroToday.
๐น DFS benefit, esp. in PD-L1-high pts
๐น Neoadjuvant chemo? Nivo benefit remains
๐น #NIAGARA vs. risk-adapted IO timing debate
๐น #MODERN study: Can ctDNA guide treatment intensity?
#WatchNow > https://t.co/JlbPEP4rSZ
#CheckMate274 analysis shows improved outcomes for #BladderCancer patients with adjuvant nivolumab. @MattGalsky @TischCancer sits down with @UroDocAsh @MDAndersonNews to discuss on UroToday.
๐น DFS benefit, esp. in PD-L1-high pts
๐น Neoadjuvant chemo? Nivo benefit remains
๐น #NIAGARA vs. risk-adapted IO timing debate
๐น #MODERN study: Can ctDNA guide treatment intensity?
#WatchNow > https://t.co/JlbPEP4rSZ
Here are the Top 10 Trials in GU Cancer for February 2025, curated by @Larvol CLIN and Bluestar BioAdvisors.
#LARVOL #Oncology #GUCancer #CancerResearch #ClinicalTrials #OncologyInsights #TALAPRO2 #CheckMate274 #NIAGARA
Engage with some of the top voices on X from the field of GU Cancer:ย @DrChoueiri | @montypal | @neerajaiims | @PGrivasMDPhD | @tompowles1 | @DrYukselUrun | @TiansterZhang | @shilpaonc | @apolo_andrea | @DrRanaMcKay | @SuyogCancer
#checkmate274 Deep Research
Adjuvant nivolumab vs placebo for high-risk muscle-invasive #UrothelialCarcinoma: Additional efficacy outcomes including overall survival in patients with #MIBC from #CheckMate274. Presentation by @MattMilowsky @UNC_Lineberger. #GU25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/L5CEsdLUmY
At @ASCO - #GU25, Dr. @sonpavde highlights the CheckMate 274 trial while talking to @brunolarvol in a Quick Takes session.
#LARVOL #GUCancer #CheckMate274 #Oncology #CancerResearch #GenitourinaryCancer
@ERPlimackMD with killer discussion setting the scene for the #NIAGARA โsandwichโ & #Checkmate274, both practice changing for our pts w #bladdercancer. @ASCO #GU25
@MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing @ALLIANCE_org #MODERN trial! @ASCO #GU25
๐ฅ Don't miss @sonpavde's thoughts on first-line #perioperative #PDL1 therapy for advanced #BladderCancer, including the #CheckMate274, #AMBASSADOR, and #NIAGRA trials.
๐ Watch Here: https://t.co/b76OU3ISKP
๐ฅ Don't miss @sonpavde's thoughts on first-line #perioperative #PDL1 therapy for advanced #BladderCancer, including the #CheckMate274, #AMBASSADOR, and #NIAGRA trials.
๐ Watch Here: https://t.co/b76OU3ISKP
Dr @DiMariaJiang discusses results of the #CheckMate274 study on patients with muscle-invasive #urothelialcarcinoma. See her full analysis here: https://t.co/BJbLS8KCYX
Watch all content from our Best of ASCOยฎ๏ธ GU & GI Cancers conference here: https://t.co/rWtXrP9BpO
#MedOnc
๐๏ธ In episode 309 of the @Uromigos, @brian_rini and @tompowles1 talk with @MattGalsky about the #OS signal data from #CheckMate274, which analyzed the use of #adjuvant #nivolumab in patients with #MIBC.
๐ Listen Here: https://t.co/mVK0xp4Sqk
Last Seen Hashtags on Sotwe
teenageer
Seen from Greece
ไนณ่ถ่กฃ
Seen from Japan
momsonn Teenageer() +filter:native_video
Seen from United States
เนเธขเนเธเนเธเธทเนเธญเธ
Seen from Thailand
lovedolltoyfactory
tamilnaduleaked
Seen from United Kingdom
bop chav
Seen from Egypt
gaziantepesc
Seen from Turkey
omegle porn filter:videos
Seen from France
lolabunny
Seen from India
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
113.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.7M followers
Taylor Swift
@taylorswift13
83.6M followers
Lady Gaga
@ladygaga
75.1M followers
Virat Kohli
@imvkohli
72.9M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.9M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers